Innate Pharma S.A. (IPHA)
Automate Your Wheel Strategy on IPHA
With Tiblio's Option Bot, you can configure your own wheel strategy including IPHA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IPHA
- Rev/Share 0.1557
- Book/Share 0.109
- PB 14.2178
- Debt/Equity 3.5086
- CurrentRatio 2.5997
- ROIC -0.5943
- MktCap 142809570.036
- FreeCF/Share -0.0899
- PFCF -19.5979
- PE -2.5389
- Debt/Assets 0.2791
- DivYield 0
- ROE -2.6293
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides
Published: May 23, 2025 by: Business Wire
Sentiment: Neutral
MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the presentation of long-term follow-up data from the Phase 2 TELLOMAK clinical trial evaluating lacutamab, an anti-KIR3DL2 monoclonal antibody, in patients with Sézary syndrome (SS) and mycosis fungoides (MF), two rare and aggressive forms of cutaneous T-cell lymphoma (CTCL). The results will be presented at the American Society of Clinical Oncol.
Read More
Outcome of Innate Pharma's 2025 Annual General Meeting
Published: May 23, 2025 by: Business Wire
Sentiment: Neutral
MARSEILLE, France--(BUSINESS WIRE)-- #AG--Outcome of Innate Pharma's 2025 Annual General Meeting.
Read More
Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting
Published: May 19, 2025 by: Business Wire
Sentiment: Neutral
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that four abstracts with Innate's drugs in clinical development have been accepted for the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, taking place May 30-June 3, 2025 in Chicago, Illinois. “We are looking forward to participating in the ASCO Annual Meeting 2025, where four abstracts with Innate's drugs in clinical developmen.
Read More
Innate Pharma S.A. (IPHA) Q1 2025 Earnings Call Transcript
Published: May 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Innate Pharma S.A. (NASDAQ:IPHA ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Corporate Participants Henry Wheeler - VP, IR and Communications Jonathan Dickinson - Chief Executive Officer Yannis Morel - Chief Operating Officer Sonia Quaratino - Chief Medical Officer Frederic Lombard - Chief Financial Officer Conference Call Participants Daina Graybosch - Leerink Partners Swayampakula Ramakanth - H.C.
Read More
Innate Pharma announces conference call and webcast for Q1 2025 business update
Published: May 06, 2025 by: Business Wire
Sentiment: Neutral
MARSEILLE, France--(BUSINESS WIRE)-- #innatepharma--Innate Pharma announces conference call and webcast for Q1 2025 business update.
Read More
Innate Pharma Files Its 2024 Universal Registration Document (Document d'enregistrement universel) and 2024 Annual Report on Form 20-F
Published: April 30, 2025 by: Business Wire
Sentiment: Neutral
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2024 Universal Registration Document (Document d'enregistrement universel) for the year ending December 31, 2024 with the French market authority “Autorité des Marchés Financiers” (“AMF”) on April 30, 2025. It can be downloaded (in French) on the Company's website and on the AMF's website. The Company also announced today the fil.
Read More
Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting
Published: April 29, 2025 by: Business Wire
Sentiment: Neutral
MARSEILLE, France--(BUSINESS WIRE)-- #AACR--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today shared new preclinical data for IPH4502, its novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2025. Nectin-4 targeting is validated by enfortumab vedotin (EV), an ADC with a monomethyl auristatin E (MMAE) payload,.
Read More
Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference
Published: March 25, 2025 by: Business Wire
Sentiment: Neutral
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference.
Read More
Innate Pharma: Moving Into The Padcev Space
Published: March 21, 2025 by: Seeking Alpha
Sentiment: Positive
Innate Pharma's diverse pipeline, including lacutamab, IPH6501, and IPH4502, shows promising clinical activity and potential for significant milestones in 2025. Lacutamab, a key asset, received US FDA Breakthrough Therapy designation, enhancing its development prospects and partnership potential. Financially, IPHA has a cash runway until the end of 2025, but may face a cash crunch, likely requiring equity raises or partnerships, in my opinion.
Read More
Innate: Lacutamab Treatment Program Moves Forward With Potential Expansion
Published: February 20, 2025 by: Seeking Alpha
Sentiment: Positive
Positive results achieved in the open-label phase 2 TELLOMAK study, using lacutamab for the treatment of patients with relapsed/refractory Sezary Syndrome; Patients achieved a confirmed Objective Response Rate of 37.5%. Release of data from phase 2 study, using lacutamab for the treatment of patients with Peripheral T-cell Lymphoma, expected in 2025. Company actively seeking to establish a collaboration agreement with a pharmaceutical company to initiate a phase 3 study using lacutamab to target patients with Cutaneous T-Cell Lymphoma.
Read More
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
Published: February 17, 2025 by: Business Wire
Sentiment: Neutral
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces U.S. FDA granted Breakthrough Therapy Designation to lacutamab for relapsed or refractory Sézary Syndrome.
Read More
About Innate Pharma S.A. (IPHA)
- IPO Date 2019-10-17
- Website https://www.innate-pharma.com
- Industry Biotechnology
- CEO Mr. Jonathan E. Dickinson B.Sc., M.B.A.
- Employees 181